Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Seaport Therapeutics Q3 2026 Results: Net Loss of $26.4M, Loss Widens

Seaport Therapeutics is a clinical-stage therapeutics company that recently transitioned to public markets, reporting 53,530,550 shares of voting common stock outstanding as of October 2026. The filing indicates the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, focusing on advancing its clinical pipeline and research programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-26.3-22.4
Net income-26.4-22.5
EPS (diluted, $ a share)$-0.49$-9.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SPTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Seaport Therapeutics, Inc.: key numbers

Share price
$19.12Close, Nov 16
Market cap
$1.02B
Shares outstanding
53.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Seaport Therapeutics, Inc.

All →
7:30 AM ET Form 4
Insider Buying

Seaport Therapeutics Director Denice Torres Buys $99.3K of Stock

Denice Torres, Director, bought 5,000 shares of Seaport Therapeutics, Inc. at $19.86 a share, worth $99.3K in total on Nov 3, 2026. Shares held after the trade: 5,000.

Value
$99.3K
Shares
5,000
Price
$19.86
Role
Director
Trade date
Nov 3, 2026
7:04 AM ET 8-K
Financial Results

Seaport Therapeutics Financial Results

Seaport Therapeutics reported third quarter 2026 financial results, ending the period with $403.8 million in cash and investments. The company highlighted clinical progress, including the dosing of the first patient in a Phase 2a trial for GlyphAgo and positive Phase 1 driving simulation data for GlyphAllo. Management expects current capital to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.

“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.”

Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics

“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts. There are a billion people living with mental illness – waiting and hoping for better medicines. We are committed to our mission to bring better days to patients and their families.”

Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.